Navigation Links
Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit
Date:2/28/2008

Company Brings Together Distinguished Panel of Dental Experts to Advance

the Art, Science and Knowledge of CCLAD in Dentistry

LIVINGSTON, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today reported that earlier this month the Company hosted the First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit in New Orleans. The Summit welcomed a distinguished panel of dental experts who gathered to discuss advancements in the scientific and clinical practice communities toward the common goal of advancing the art, science and knowledge of CCLAD in dentistry.

Joe Martin, Chief Executive Officer of Milestone, noted, "Through this Summit, Milestone hoped to provide a forum for open and objective discussion by a unique blend of academia, key opinion leaders and practicing dentists. The in-depth discussion, debate and exchange of ideas that occurred helped to provide Milestone with confirmation that the STA(TM) System and the CompuDent(R) (formerly known as The WAND(R)) are significant improvements over traditional injection techniques."

The two day Summit was chaired by noted dental anesthetic expert, Stanley Malamed, DDS, Professor of Anesthesia and Medicine School of Dentistry at the University of Southern California School of Dentistry. Dr. Malamed is also a Diplomate of the American Dental Board of Anesthesiology, as well as a recipient of the Heidebrink Award from the American Dental Society of Anesthesiology and the Horace Wells Award from the International Federation of Dental Anesthesia Societies. He has authored more than 100 scientific papers and 16 chapters in various medical and dental journals and textbooks in the areas of physical evaluation, emergency medicine, local anesthesia, sedation and general anesthesia. In addition, Dr. Malamed is the author of three widely used textbooks, published by C
'/>"/>

SOURCE Milestone Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. King of Talk Celebrates Milestone With Quaker, The King of Hearts
2. Sikorsky Aircraft and PHI Celebrate Fleet Expansion and 20K Milestone at Heli-Expo
3. IOF hails WHO report and FRAXtm Web site as milestones in osteoporosis prevention and treatment
4. Milestone Scientific to Exhibit at the Chicago Dental Societys 143rd Midwinter Meeting
5. Milestone Scientific Appoints Dental Industry Veteran Scott Mahnken as New Director of Marketing
6. Vendormate Storms into 2008 with Major Milestones for Hospital Vendor Compliance
7. Tethys Bioscience Hits Key Milestones With Series C Funding, Opening of CLIA Laboratory
8. TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience
9. Transition Therapeutics Announces Milestone Payment from Elan
10. Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors
11. IBM reports milestone in silicon nanophotonics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...LE, Tenn., Dec. 2 TeamHealth ( www...t Florida with the acquisition of Naples-based Eme...uary 2002, EPN has held an exclusive contract with...lities at the Downtown Naples Hospital, North Napl...also provides the staffing for two stand-alone urg...
(Date:12/2/2009)...he official congress of the European Association o...he European Society of Cardiology, where technique...nted. , New case reports will be presented at t...lighting the role of this new technology. , Now...s, it is likely that non-invasive imaging will gai...
(Date:12/2/2009)... Revolutionary new cell phones that direct mi...be available in early 2010 from Aerius Internation...er 2, 2009 -- Revolutionary new cell phones that d...rs will be available in early 2010 from Aerius Int...d with a Green Technology Award in wireless commun...
(Date:12/2/2009)... Dec. 2 The American He... Directors today announced Alan F. Dowling, PhD, w...er health information management (HIM) leader. Dr...e includes academia, systems management, strategic...rofit executive leadership. He is scheduled to ta...
(Date:12/2/2009)...Today,s Washington Post Highlights Dangers ...- If the Catholic bishops have their way, many ...ke for granted may be under threat. The pressure ...bate over healthcare reform has been widely report...s of the likely impact if that pressure to influen...
Breaking Medicine News(10 mins):Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2Health News:Media alert: EUROECHO 2009 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2
...Products offer biologically safe water through poi...on, NEW YORK, June 3 Nephros, Inc., a medical,de...biting its Dual Stage,Ultrafilter products at the ...ss of the Nephros online,hemodiafiltration technol...
..., N.J., June 3 BD (Becton,Dickinson and Company) ...,announced today that it would present at the Gold...nference on Wednesday, June 11, 2008, at 4:20,p.m....r replay,through Wednesday, June 18, 2008., BD, a...
...N.J., June 3 HLTH Corporation,(Nasdaq: HLTH ) to...e,agreement to sell its ViPS segment to General Dy...d subsidiary of General Dynamics Corporation,(NYSE...d under the Hart-Scott-Rodino Act., ViPS provides...
...ells can produce tiny magnetic nuggets after the i...ists have found. The gene MagA could become a valu... body via magnetic resonance imaging (MRI), says X...to make mammalian cells have a magnetic signature,...
...., June 3 MedAmerica reports 2007 was its,17th co...sults. In,addition, MedAmerica outperformed the lo...years with a compound annual sales rate of 10%. (L...America,Insurance Company of Florida (Home Office:...
...June 3 On June 7, 2008 the Philadelphia,Physician...hensive,physicals for student athletes in the Phil...sylvania are required to receive a physical to be ...life-threatening conditions., The 2008 program wi...
Other Medicine News:Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 2Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 3Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 4Health News:HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million 2Health News:HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million 3Health News:Philly's Top Doc's Organize to Help Prevent Young Athlete Deaths in Philadelphia 2
(Date:12/2/2009)..., PLEASANTON, Calif., Dec. 2 /PRNewswire-FirstCal... today that the United States Food & Drug Admi...se for its licensed nucleic acid test, to screen s...dual donations. The test, called the cobas® T...tem, is a qualitative, in-vitro test for the simul...
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 /PRNewswire/...ing a late-breaking presentation on Tasigna® ...yeloid leukemia, demonstrate the strength of the c...e of patients. ,, The new data, at the 51st Am...and Exposition, highlight the company,s current th...
(Date:12/1/2009)..., REDONDO BEACH, Calif., Dec. 1 Re...their Elective Single Embryo Transfer (eSET) Encou...for patients with good embryo quality and a good p...ce of twins by transferring a single embryo. ,,...logy today is reducing the number of multiple preg...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2Craneware Announces Fiscal Year End Results 56424 1Craneware Announces Fiscal Year End Results 56424 2Craneware Announces Fiscal Year End Results 56424 3Dr Smith Comes to Washington 3A Angry Physicians From All 50 States Rally in DC on Sept 10 56422 1Dr Smith Comes to Washington 3A Angry Physicians From All 50 States Rally in DC on Sept 10 56422 2Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 56420 1Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 56420 2
...all at 9:00 AM ET Today , , CORAL GABLES, Fla.,...asdaq: CPRX ) today announced top-line results f...ine addiction. The data from the trial showed tha...ance in the primary endpoint -- that a significant...han placebo-treated subjects were cocaine-free dur...
...nd Evidence of Biological Activity in 9 of 12 Pati...7 Leading U.S. Medical Centers , , SAN DIEGO, May...data from the Calcium Up-Regulation by Percutaneou...e (CUPID), a First-in-Human Phase 1/2 Clinical Tri...merican Society of Gene Therapy Meeting. , , Th...
Other Medicine Technology:Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 2Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 3Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 4Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting 2Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting 3Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting 4
...ual acuity system allows you access to the most po...s 10 different optotypes, crowding bars, random se...d characters. Random character sequencing eliminat...gle letter, single line and multiple line selectio...
...ght Probes provide the surgeon with an indirect il...e to be easily visualized through the laser micros...catter technique, the surgeon can enhance visualiz...ap edge folds, corneal flap striae and flap alignm...
...ual acuity system allows you access to the most po...s 10 different optotypes, crowding bars, random se...d characters. Random character sequencing eliminat...gle letter, single line and multiple line selectio...
...channel sleep diagnostic collection software. Sand...eep diagnostic collection software offers customiz...t recording or post recording. The scoring display...p events including current number of events, frequ...
Medicine Products: